About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc. is a late clinical-stage biopharmaceutical company. The Company if focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a novel therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). It is developing TP-03 as an eye drop. It is also focused on developing additional clinical-stage product candidates, including TP-04 and TP-05. TP-04 is being developed for the treatment of rosacea and TP-05 for Lyme prophylaxis and community malaria reduction.